Why It’s Illegal to Call a Drug “Stroebenazoline”
Credibility score: 69/100 — Mostly Credible. Mixed credibility - some claims are solid, others need verification.
BSmeter analyzed "Why It’s Illegal to Call a Drug “Stroebenazoline”" and rated it 69/100 for credibility (a BS score of 31/100 — mostly credible), on 2026-09-20. Its weakest claim — "Claims 'lookalike soundalike' drugs cause 'at least a death a day' and 'million injuries a year' — then calls it 'life and death.' 💀" — scored 45/100 and was flagged as emotional button. 22 claims were checked against the video transcript. Scores are produced by BSmeter's AI analysis of the transcript, not independent human verification.
Claims analyzed
Video opens with a highlight reel preview of drug naming complexities. — Just Vibes (50/100)
A rapid-fire list of drug names and a quick setup for the 'complex process' of naming them. It's just setting the stage, no claims yet. 😈
Sets up a dramatic reveal about drug names — then just states a fact. 😈 — No Frame (75/100)
He's building up the mystery, but the 'three names' thing is just how it works. No trick here, just a bit of theater. 🎭
Claims 'lookalike soundalike' drugs cause 'at least a death a day' and 'million injuries a year' — then calls it 'life and death.' 💀 — Emotional Button (45/100)
He's hitting you with a 'death a day' stat from the WHO to make drug naming sound like a constant crisis. It's a real problem, but the framing is pure drama. 🔥
States there are 'about 600' drug stems, then gives examples. 😈 — No Frame (75/100)
He's just laying out the rules for drug naming. No hidden agenda, just explaining the system. 📝
Claims initial syllables are 'just sounds' for uniqueness, not scientific meaning. 😈 — No Frame (75/100)
He's pulling back the curtain on how these names are made. It's not always deep science, just practical naming. 💡
Drug names too long: six syllables when five is max. That's a rule, not a suggestion. 😈 — No Frame (75/100)
He's just laying out the rules for drug naming — no tricks here, just the cold, hard facts of bureaucracy. 📜
Bad letters for drug names: H, K, J, W, Y are out. Global reach, global rules. 🌍 — No Frame (75/100)
More rules for drug naming, this time about global pronunciation. It's a practical constraint, not a conspiracy. 🗣️
Can't name a drug after his channel: 'Half as Interesting' is out. Also, mixing up 'bowl' and 'bol' could lead to anabolic steroids instead of decongestants. 💀 — No Frame (75/100)
He's explaining the very real, very dangerous problem of sound-alike drug names. It's not a joke when someone gets the wrong meds. 💊
A 'laundry list' of forbidden letter combos and word parts. He's not wrong, the rules are endless. 📜 — No Frame (75/100)
He's just stating the sheer volume of naming restrictions. It's a bureaucratic nightmare, not a trick. 😈
They use a tool called 'PA' to score name similarity. Sounds like a real thing, but no details. 🤷♂️ — Anonymous Authority (45/100)
He mentions a tool called 'PA' without explaining what it is. A name and no context is just a whisper. 👻
Brand names skip WHO/Eucon Council. Different rules for different names. 🏷️ — No Frame (75/100)
He's correctly distinguishing between generic and brand name approval processes. Two different beasts, two different masters. ⚖️
FDA approves brand names, with a 'helpful 42-page guide.' And big pharma pays consultants half a million for names. 💸 — No Frame (75/100)
The FDA does have extensive guidelines, and pharma does spend insane money on branding. This is just the brutal truth of the industry. 💰
Explaining drug naming rules for generic names and stems — straightforward facts. — No Frame (75/100)
He's laying out the actual, specific rules for drug names. No tricks, just the regulations. 😈
Explaining why 'Flexipo' fails due to similarity and misleading abbreviation — clear rules. — No Frame (75/100)
He's showing how names get rejected for sounding too much like others or using forbidden abbreviations. It's all about patient safety. 😈
Citing general guidelines for drug name length — straightforward criteria. — No Frame (75/100)
He's just listing the common length guidelines for drug names. Simple, direct, no hidden agenda. 😈
Illustrating drug name confusion with a real-world 'Dilicor' example — a cautionary tale. — No Frame (75/100)
He's using a real, documented case of drug name confusion causing harm. This isn't a trick; it's a warning. 😈
Explaining why names implying efficacy are forbidden — a clear regulatory principle. — No Frame (75/100)
He's explaining a core rule: no drug names that promise results. It's a direct statement of regulation. 😈
Citing examples of rejected drug names for implying efficacy — real-world applications of the rule. — No Frame (75/100)
He's giving actual examples of names like 'Novo Rapid' and 'Regain' that were rejected for promising too much. This is just how it works. 😈
Drug names can't have numbers or sound like dosages — that's just common sense, mortals. — No Frame (75/100)
He's laying out the rules for drug naming, and honestly, it's a pretty basic safety measure. No trickery here. 😈
He's trying to game the system with 'Wendozi' — then admits it's too close to 'Wegovy.' Classic mortal optimism. 💀 — Confidence Mismatch (45/100)
He's so sure 'Wendozi' is a winner, then immediately finds a glaring conflict. That's not confidence, that's wishful thinking. 🔥
Cool Earth sponsor read — saving the planet by giving cash to indigenous communities. Standard pitch. 😈 — Sponsored (50/100)
Ah, the mid-roll. He's pitching Cool Earth, an organization that protects ecosystems by funding indigenous communities. It's an ad, plain and simple. 💰
A call to action for donations to save the rainforest. Standard pitch. 🌳 — Sponsored (50/100)
This isn't a claim, it's a direct plea for cash. They want your money for the rainforest. 💸
See the full analysis with sources and timestamps →